Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The test is intended to detect FLT3 mutations in order to select patients for treatment with Novartis' Rydapt, and has also been approved by the US FDA.

Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.


360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.